Saint-Gobain Life Sciences Announces $77 Million Expansion Program
Through the program, the company will introduce seven new manufacturing sites that will be completed and operational by the end of 2020.
Saint-Gobain Life Sciences announced the launch of its EUR 70-million (US$77-million) global expansion program on Nov. 21, 2019. Through the program, the company will introduce seven new manufacturing sites that will be completed and operational by the end of 2020.
According to a company press release, the program was kicked off with the construction of the company’s Bangalore, India, site in September of 2019, and, recently, the company ended construction on its Largo, FL, facility for the production of its C-Flex tubing, molded connections, and assemblies. The additional facilities will be located in Beaverton, MI; Charny, France; Dublin, Ireland; Hangzhou, China; and Songdo, South Korea.
“This is an exciting time in our business,” said Jean Angus, CEO, Saint-Gobain Life Sciences, in the press release. “This is the execution of a multi-year plan to expand our global manufacturing footprint, which will enhance our ability to service our Life Sciences customers globally with redundant manufacturing facilities. We are increasing the regional availability of our products and our ability to meet customers’ growing demands.”
Source: Saint-Gobain Life Sciences
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
